From: FiercePharma

By: Kyle Blankenship






Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst

Between AbbVie’s two newly approved blockbusters-in-waiting, psoriasis med Skyrizi’s booming sales have drawn some analysts’ eyes away from highly-touted rheumatoid arthritis drug Rinvoq. But among physicians, Rinvoq is becoming a darling, one analyst says––and an “AbbVie halo” could be major part of that…(read more).